577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir

Saturday, October 19, 2024

2:09 PM - 2:21 PM US PT

Location: 403 A

Presenting Author(s)

Amy E. Colson

Research Director
Community Resource Initiative
Boston, MA, United States

Slides

Co-Author(s)

GE

Gordon E. Crofoot, n/a

The Crofoot Research Center
Houston, Texas, United States
PJ

Peter J. Ruane, n/a

Ruane Clinical Research
Los Angeles, California, United States
MN

Moti N. Ramgopal, n/a

Midway Immunology & Research Center
Fort Pierce, Florida, United States
AW

Alexandra W. Dretler, n/a

Metro Infectious Disease Consultants
Decatur, Georgia, United States
Ronald G. Nahass, MD

President
ID Care
Hillsborough, New Jersey, United States
GI

Gary I. Sinclair, n/a

Prism Health North Texas
Dallas, Texas, United States
MB

Mezgebe Berhe, MD, MPH

Infectious Disease specialist
North Texas Infectious Diseases Consultants
Dallas, Texas, United States
FS

Fadi Shihadeh, n/a

Gilead Sciences
Foster City, California, United States
SL

Shan-Yu Liu, PhD

Gilead Sciences Inc
Foster City, California, United States
SK

Stephanie Klopfer, n/a

Merck & Co., Inc.
Rahway, New Jersey, United States
SM

Sharline Madera, MD, PhD

Gilead Sciences, Inc.
Foster City, California, United States
HD

Hadas Dvory-Sobol, PhD

Gilead Sciences
Foster City, California, United States
MR

Martin Rhee, MD

Gilead Sciences
Foster City, California, United States
EG

Elizabeth G. Rhee, n/a

Merck & Co., Inc.
Rahway, New Jersey, United States
JB

Jared Baeten, MD, PhD

Gilead Sciences
Foster City, California, United States
Joseph J. Eron, MD

Professor
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, North Carolina, United States

Disclosure(s):

Amy E. Colson: Gilead Sciences, Inc.: Advisor/Consultant; ViiV: Honoraria

Gordon E. Crofoot, n/a: AbbVie: Grant/Research Support; Gilead Sciences, Inc.: Grant/Research Support; Janssen: Grant/Research Support; Merck: Grant/Research Support; ViiV: Grant/Research Support

Peter J. Ruane, n/a: Gilead Sciences, Inc.: Advisor/Consultant, Honoraria; ViiV: Advisor/Consultant, Honoraria

Moti N. Ramgopal, n/a: AbbVie: Honoraria; Gilead Sciences, Inc: Advisor/Consultant, Honoraria; Merck: Advisor/Consultant; ViiV: Advisor/Consultant, Honoraria

Alexandra W. Dretler, n/a: AbbVie: Grant/Research Support; Gilead Sciences, Inc.: Grant/Research Support; ViiV: Advisor/Consultant, Grant/Research Support

Ronald G. Nahass, MD: Abbvie: Honoraria; Arbutus: Grant/Research Support; Gilead Sciences, Inc.: Grant/Research Support; Merck: Grant/Research Support; Vir: Grant/Research Support

Gary I. Sinclair, n/a: Abbvie: Advisor/Consultant, Grant/Research Support, Honoraria; Gilead Sciences, Inc.: Advisor/Consultant, Grant/Research Support; Janssen: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; Theratechnologies: Advisor/Consultant, Grant/Research Support, Honoraria; ViiV: Advisor/Consultant, Grant/Research Support, Honoraria

Mezgebe Berhe, MD, MPH: No financial relationships to disclose

Fadi Shihadeh, n/a: Gilead Sciences, Inc: employee and shareholder

Shan-Yu Liu, PhD: Gilead Sciences, Inc.: employee and shareholder

Stephanie Klopfer, n/a: Merck & Co., Inc.: subsidiary and shareholder; Merck Sharp & Dohme LLC: employee

Sharline Madera, MD, PhD: Gilead Sciences, Inc.: employee and shareholder

Hadas Dvory-Sobol, PhD: Gilead Sciences, Inc.: employee and shareholder

Martin Rhee, MD: Gilead Sciences, Inc.: employee and shareholder

Elizabeth G. Rhee, n/a: Merck & Co., Inc.: subsidiary and shareholder; Merck Sharp & Dohme LLC: employee

Jared Baeten, MD, PhD: Gilead Sciences, Inc.: employee and shareholder

Joseph J. Eron, MD: Gilead Sciences: Advisor/Consultant, Grant/Research Support; Invivyd: Safety Monitoring Board; Merck & Co: Advisor/Consultant